Position in NKTR
as of Jun 30, 2026
· filed Aug 17, 2026
Position Value
$481,828
+$449,377 QoQ
Shares Held
6,902
+5604.1% QoQ
Ownership
0.020%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#151
of 239 holders
Holding Since
Mar 2020
2 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in NKTR Over Time
Shares Held
Position Value (USD)
Derivatives in NKTR
reported options exposure · as of Mar 31, 2020CallValue
$323,085
CallShares
1,207
PutValue
$32,130
PutShares
120
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026CAPSTONE INVESTMENT ADVISORS, LLC holds $45,989,751 across 38 Biotechnology names. NKTR ranks #14 (1.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APGE |
Apogee Therapeutics, Inc.
|
120,000 | $15,927,600 | |
| 2 | TECH |
BIO-TECHNE Corp
|
210,000 | $14,836,500 | |
| 3 | RVMD |
Revolution Medicines, Inc.
|
7,200 | $1,348,416 | |
| 4 | RXRX |
Recursion Pharmaceuticals, Inc.
|
222,378 | $816,127 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,240 | $773,189 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,448 | $719,265 | |
| 7 | TGTX |
Tg Therapeutics, Inc.
|
12,611 | $692,848 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,899 | $571,655 |
All Filings in NKTR
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $481,828 | 6,902 | Shares | Defined | 2026-08-17 | |
| 2020-03-31 | $32,451 | 1,818 | Shares | Sole | 2021-06-21 | |
| 2020-03-31 | $323,085 | 18,100 | Call | Sole | 2021-06-21 | |
| 2020-03-31 | $32,130 | 1,800 | Put | Sole | 2021-06-21 | |
| No filing history on record for this holder in this stock. | ||||||